Business
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm's leadership in complex generics and highlights Taiwan's growing recognition as a trusted contributor to the global pharmaceutica
About this update from Scinopharm Taiwan, Ltd.
[{"type":"text","content":"TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm's leadership in complex generics and highlights Taiwan's growing recognition as a trusted contributor to the global pharmaceutical industry.","length":556,"tagName":"p"},{"type":"text","content":"Multiple Sclerosis affects approximately 2.9 million people worldwide. According to the U.S. National MS Society, there are nearly 1 million patients in the United States alone. Verified Market Reports estimates that the global market size for Glatiramer Acetate was USD 1.5 billion in 2024 and is projected to reach USD 2.8 billion by 2033. In response to this significant opportunity, ScinoPharm has invested heavily in its process development and manufacturing capabilities, successfully mastering this high-barrier process after years of dedicated R&D and ultimately positioning itself to compete in its USD ~700 million U.S. market.","length":641,"tagName":"p"},{"type":"text","content":" Pioneering R&D: ScinoPharm Scientists Decode the Complexity of Glatiramer Acetate Manufacturing ","length":99,"tagName":"p"},{"type":"text","content":"Since its approval in 1996, Glatiramer Acetate (GA) has been recognized as one of the most challenging complex synthetic polypeptides globally. To address the unique nature of such products, the U.S. FDA even established a dedicated regulatory pathway for Non-Biological Complex Drugs (NBCDs).","length":298,"tagName":"p"},{"type":"text","content":"Unlike conventional small molecules, GA is not a single defined entity but a peptide copolymer mixture composed of millions of polypeptide chains with varying lengths and amino acid sequences. It lacks a fixed molecular structure, a specific sequence, and a uniform molecular weight, so it cannot be fully characterized using standard analytical methods typically applied to biologics such as monoclonal antibodies. This complexity results in significant challenges for quality control, manufacturing reproducibility, and equivalence assessment."...